# Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

Study · id `cardio:ct-nct06688123` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06688123](<https://clinicaltrials.gov/study/NCT06688123>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06688123

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.

## Technical summary

Registry record NCT06688123. Randomized; no masking; primary purpose treatment. Start 2025-01-08 (actual); primary completion 2026-04-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 275 participants (enrolled count; ClinicalTrials.gov record NCT06688123, source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)
- Started: 2025-01-08 (actual) (ClinicalTrials.gov record NCT06688123, source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)
- Primary completion: 2026-04-22 (actual) (ClinicalTrials.gov record NCT06688123, source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)
- Completion: 2026-04-22 (actual) (ClinicalTrials.gov record NCT06688123, source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06688123, source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06688123-2026-06-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
- Condition: Type 2 Diabetes
- Intervention (Drug): SHR-3167
- Intervention (Drug): SHR-3167
- Intervention (Drug): Insulin glargine
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 0589acf3cb2744c13b3e8ddda8003528f157db6a7f879f8f2df3295bd03066b1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
